|
|
Infliximab Therapeutic Drug Monitoring
Serum Infliximab and Total Anti-Infliximab Antibodies
Infliximab (Remicade®), is a chemeric human-mouse monoclonal antibody
directed against tumour necrosis factor-alpha (TNF ), approved for use in the
treatment of various chronic inflammatory diseases including rheumatoid
arthritis, severe crohn's disease and ankylosing spondylitis. We measure serum
infliximab using an in-house ELISA method.
|
|
Download Information Leaflet
here...
|
|
Test:
|
Infliximab Therapeutic Drug Monitoring
|
|
Laboratory
|
Clinical Biochemistry |
|
Specimen Type:
|
0.5 mL Serum |
|
Storage:
|
-20°C prior to dispatch |
|
Posting Details:
|
Ambient temperature, first class post |
|
Posting Address:
|
Department of Clinical Biochemistry, City Hospital, Dudley
Road, Birmingham B18 7QH |
|
Clinical Use:
|
Effective use of Infliximab in clinical practice. To assess reasons for a
lack of clinical response. |
|
Pricing:
|
Serum Infliximab: £30
Anti-Infliximab antibodies: £37 |
|
Turnaround:
|
Serum Infliximab Assay- within 3 working days
Anti-Infliximab Antibodies Assay - within 7 working days |
|
External QA Scheme:
|
Not Applicable |
|
CPA Accredited Lab/Test:
|
Yes, CPA Full Accreditation |
|
Key Contacts:
|
Tel: 0121 507 3441
Email:
info@cityassays.org.uk
|
|
|
